thebench.bio #1 Ecosystem for the Bio-Tech Industry

Regulatory Daily Summary

Regulatory Daily Summary: What Happened on November 12, 2026

FDA adds potential vision-loss warning to GLP-1 labels

The agency also issued potency guidance for cell and gene therapies and opened comments on its rare-disease initiative.

  • Updated
  • Read from 10 articles, 8 publications
  • P B B P +2

Today in brief

The FDA directed makers of all GLP-1 receptor agonists to warn about a rare condition that can cause sudden vision loss in one eye.1 It issued guidance on potency controls for cell and gene therapies and opened its Rare Disease Framework Initiative to public comments through December 11.23

Kamau Therapeutics said the FDA granted its sickle cell therapy nula-cel RMAT designation, while Biolojic Design received clearance to begin testing BD200 in a Phase 1 study.45 The FDA and European Medicines Agency waived pediatric study requirements for Shanton Pharma’s gout candidate SAP-001.6

FDA requires a potential vision-loss warning across GLP-1 labels

The FDA directed holders of applications for all GLP-1 receptor agonists to add a warning about nonarteritic anterior ischemic optic neuropathy, or NAION, to product labeling.1 NAION is an uncommon condition that can cause abrupt, painless vision loss in one eye.1

The FDA began its review after a July 2024 observational study and found the risk remained rare after assessing clinical and real-world evidence.1 The agency is asking prescribers to tell patients to report sudden vision changes promptly.1

FDA guidance sets a flexible approach to potency controls for cell and gene therapies

The FDA issued guidance on protecting potency in cellular and gene therapy products through manufacturing and material controls, testing, and lot-release assays.2 The guidance says these measures should help ensure each released lot can produce its intended therapeutic effect.2

Lavakumar Karympudi of Moffitt Cancer Center said the guidance gives developers more direction on potency assays, drawing on the FDA’s experience with different cell types.2 Max Maletta of ProBIO said the regulatory emphasis could pose a risk to autologous therapies, which are made from a patient’s own cells.2

FDA opens Rare Disease Framework Initiative to comments

The FDA launched its Rare Disease Framework Initiative on October 14 and is accepting comments through December 11, 2026.3 Former FDA reviewer Paz Vellanki urged sponsors to plan chemistry, manufacturing, and controls, or CMC, earlier when a first-in-human trial could support a marketing application.3

Vellanki said sponsors often postpone biomarker assay development and dose selection until late in Phase 2, though manufacturing or assay problems can delay trials after FDA protocol clearance.3 She said assay delays are especially concerning when enrollment depends on identifying patients with a specific biomarker.3

FDA grants nula-cel RMAT status based on preliminary data from three patients

Kamau Therapeutics said the FDA granted regenerative medicine advanced therapy, or RMAT, designation to nula-cel, its investigational gene-corrected therapy for sickle cell disease.4 The designation drew on preliminary findings from the ongoing Phase 1/2 RESTORE study.4

All three patients treated with the optimized manufacturing process became transfusion-independent and had no vaso-occlusive events, the company said.4 The two patients followed for more than six months had hemoglobin S levels below 20%. The findings have not been peer reviewed or compared with a control group.4

Kamau plans to enroll about 15 patients ages 12 to 40, with safety as the study’s primary aim.4 The company plans to share more interim efficacy findings later in 2026 and seek an FDA meeting about the registration path.4 RMAT status does not guarantee approval or expedited review.4

FDA clears Biolojic Design’s BD200 for Phase 1 testing

The FDA cleared Biolojic Design’s investigational new drug application for BD200, allowing the company to begin clinical testing.5 Biolojic describes BD200 as an AI-designed bispecific antibody-drug conjugate targeting Trop2 and Nectin-4. The company says it is the first multibody to enter clinical trials.5

The company plans to start a global Phase 1 study in the coming weeks in patients with selected solid tumors expressing both targets.5 The trial is designed to assess safety, tolerability, pharmacokinetics, and preliminary efficacy.5

BD200 is designed so either binding arm can engage either target, with a topoisomerase-inhibitor payload attached through a linker.5 Biolojic said preclinical tests found that the molecule bound both targets and adjusted to different antigen patterns on tumor cells. The company did not identify the models used.5

FDA and EMA waive pediatric studies for Shanton’s SAP-001

The FDA and European Medicines Agency waived pediatric study requirements for Shanton Pharma’s investigational gout drug SAP-001.6 The FDA cited the very low frequency of gout in children. The EMA’s product-specific waiver covers pediatric hyperuricemia except cases linked to obesity or chronic kidney disease.6

SAP-001 is a once-daily oral urate-lowering treatment intended for adults with uncontrolled or refractory gout.6 In a Phase IIb study, it showed efficacy and safety in people whose hyperuricemia had not responded to standard xanthine oxidase inhibitor treatment.6

Also worth knowing

  • P

    NICE backed NHS use of Incyte’s Zynyz for anal cancer.7

  • Abbott received FDA approval and a CE mark for a defibrillation lead intended for left bundle branch area pacing, positioning it for launch in the US and Europe.8

  • Researchers analyzing FDA AAV gene therapy investigational new drug submissions from 1995 to 2025 found rapid growth in development and recurring reasons for regulatory holds.9

  • F

    Under the FDA’s updated drug-facility operating model, effective October 21, assessors can use inspection histories from partner regulators under mutual recognition agreements when deciding whether a pre-approval inspection is needed.10

Also published